动脉样硬化中的压力颗粒:洞察力和治疗机会
Sahar Naseem1, Lijuan Sun1, Juhui Qiu1
1Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing 400030, China.
Current problems in cardiology
|July 26, 2024
概括
压力颗粒 (SG) 在动脉样硬化,心血管疾病中起着关键作用. 了解SG的形成和动态为预防和治疗动脉样硬化提供了新的治疗点.
科学领域:
- 细胞生物学 细胞生物学
- 分子医学是分子医学.
- 心血管研究的心血管研究.
背景情况:
- 动脉样硬化是心血管疾病的主要原因,由炎症和代谢功能障碍驱动.
- 压力颗粒 (SG) 是细胞聚合物,在压力下形成,与疾病有新兴联系.
- 在动脉样硬化病原体中SG的确切作用仍然不完全理解.
研究的目的:
- 综合分析压力颗粒在动脉样硬化发展中的作用.
- 调查细胞应激和动脉样硬化相关因素如何影响SG形成.
- 探索 SG 动态对益动脉生成过程的影响.
主要方法:
- 审查和分析关于压力颗粒和动脉样硬化的现有文献.
- 检查细胞应激反应及其在SG形成中的组成部分.
- 评估诸如炎症,剪切应激和氧化应激等因素如何影响SG的评估.
- 评估SG动态对内皮功能障碍,脂质代谢和免疫细胞招募的影响.
主要成果:
- 细胞应激刺激SG形成,涉及特定组件和调节基因.
- 动脉样硬化相关的因素 (炎症,OSS,OS) 调节了SG的形成.
- 改变的SG动态会影响关键的益动脉生成过程,包括内皮功能障碍和免疫反应.
- 在动脉样硬化背景下,SG与脂质代谢变化有关.
结论:
- 压力颗粒和动脉样硬化之间存在复杂的相互作用.
- 了解这种关系可能会揭示心血管疾病的新疗法策略.
- 针对SG动态为未来动脉样硬化治疗提供了一个有希望的途径.
相关概念视频
01:38Inflammation
53.3K
Overview
53.3K
01:17Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
505
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
505
01:16Clot Retraction and Fibrinolysis
5.2K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.2K